These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 23867518)

  • 1. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.
    Finke JH; Rayman PA; Ko JS; Bradley JM; Gendler SJ; Cohen PA
    Cancer J; 2013; 19(4):353-64. PubMed ID: 23867518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
    Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
    Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
    Xin H; Zhang C; Herrmann A; Du Y; Figlin R; Yu H
    Cancer Res; 2009 Mar; 69(6):2506-13. PubMed ID: 19244102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
    Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
    Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.
    Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.
    Huo M; Zhao Y; Satterlee AB; Wang Y; Xu Y; Huang L
    J Control Release; 2017 Jan; 245():81-94. PubMed ID: 27863995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
    Zhao Q; Guo J; Wang G; Chu Y; Hu X
    Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
    Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
    Front Immunol; 2020; 11():613215. PubMed ID: 33679700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis.
    He Y; Hung SW; Liang B; Zhang R; Gao Y; Chu CY; Zhang T; Xu H; Chung JPW; Wang CC
    Front Immunol; 2021; 12():641206. PubMed ID: 34367125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
    Ko JS; Rayman P; Ireland J; Swaidani S; Li G; Bunting KD; Rini B; Finke JH; Cohen PA
    Cancer Res; 2010 May; 70(9):3526-36. PubMed ID: 20406969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
    Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
    Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
    Ko JS; Zea AH; Rini BI; Ireland JL; Elson P; Cohen P; Golshayan A; Rayman PA; Wood L; Garcia J; Dreicer R; Bukowski R; Finke JH
    Clin Cancer Res; 2009 Mar; 15(6):2148-57. PubMed ID: 19276286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.
    Cohen PA; Ko JS; Storkus WJ; Spencer CD; Bradley JM; Gorman JE; McCurry DB; Zorro-Manrique S; Dominguez AL; Pathangey LB; Rayman PA; Rini BI; Gendler SJ; Finke JH
    Immunol Invest; 2012; 41(6-7):680-710. PubMed ID: 23017141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
    Panka DJ; Liu Q; Geissler AK; Mier JW
    Mol Cancer; 2013 Mar; 12():17. PubMed ID: 23497256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice.
    Abe F; Younos I; Westphal S; Samson H; Scholar E; Dafferner A; Hoke TA; Talmadge JE
    Int Immunopharmacol; 2010 Jan; 10(1):140-5. PubMed ID: 19833232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
    Finke JH; Rini B; Ireland J; Rayman P; Richmond A; Golshayan A; Wood L; Elson P; Garcia J; Dreicer R; Bukowski R
    Clin Cancer Res; 2008 Oct; 14(20):6674-82. PubMed ID: 18927310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
    Farsaci B; Donahue RN; Coplin MA; Grenga I; Lepone LM; Molinolo AA; Hodge JW
    Cancer Immunol Res; 2014 Nov; 2(11):1090-102. PubMed ID: 25092771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.